29427-69-8

Basic information

• Product Name: 3-Oxoindane-1-carboxylic acid
• Synonyms: 2,3-dihydro-3-oxo-1h-indene-1-carboxylicacid;3-oxo-2,3-dihydro-1h-indene-1-carboxylicacid;3-OXOINDANE-1-CARBOXYLIC ACID;3-OXO-1-INDAN-1-CARBOXYLIC ACID;3-OXO-1-INDANCARBOXYLIC ACID;3-OXO-INDAN-1-CARBOXYLIC ACID;1-Indanone-3-carboxylic Acid;3-Oxo-1-indan-2-carboxylic acid
• CAS NO: 29427-69-8
• Molecular Formula: C₁₀H₈O₃
• Molecular Weight: 176.17
• Product Categories: Benzocycles;pharmacetical;Carboxylic Acids;Miscellaneous;Carboxylic Acids;Fused Ring Systems;Pharmaceutical intermediate;C10;Carbonyl Compounds
• Mol File: 29427-69-8.mol

Chemical Properties

• Melting Point: 111-113 °C(lit.)
• Boiling Point: 365.01 °C at 760 mmHg
• Flash Point: 188.737 °C
• Appearance: /
• Density: 1.384 g/cm³
• Vapor Pressure: 5.72E-06mmHg at 25°C
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.67±0.20(Predicted)
• CAS DataBase Reference: 3-Oxoindane-1-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Oxoindane-1-carboxylic acid(29427-69-8)
• EPA Substance Registry System: 3-Oxoindane-1-carboxylic acid(29427-69-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39
• WGK Germany: 3
• RTECS: NK8260000
• Hazardous Substances Data: 29427-69-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Oxoindane-1-carboxylic acid is used as a key intermediate in the synthesis of various pharmaceutical compounds, such as 3-hydroxymethyl-1-indanol. Its ability to undergo enantiomeric separation on CSPs makes it a valuable component in the development of enantiomerically pure drugs, which can have significant implications for the efficacy and safety of medications.
Used in Chiral Separation Techniques:
3-Oxoindane-1-carboxylic acid is used as a test compound in the development and optimization of chiral separation techniques, such as supercritical fluid chromatography (SFC). Its enantiomeric separation on liquid chromatography chiral stationary phases (CSPs) has been reported, and the use of a new immobilized polysaccharide chiral stationary phase, CHIRALPAK IA with hexane, has been described for this purpose. This application is crucial for the advancement of chiral separation methods, which are essential in the pharmaceutical industry for the production of enantiomerically pure drugs.

Synthesis Reference(s)

Journal of the American Chemical Society, 106, p. 6702, 1984 DOI: 10.1021/ja00334a040

InChI:InChI=1/C10H8O3/c11-9-5-8(10(12)13)6-3-1-2-4-7(6)9/h1-4,8H,5H2,(H,12,13)/p-1/t8-/m1/s1

Upstream product

• 1131-15-3 2-phenylsuccinic anhydride 
• 635-51-8 2-phenylsuccinic acid 
• 7664-93-9 sulfuric acid 
• 83-33-0 inden-1-one 
• 14025-83-3 3-cyano-3-phenylpropanoic acid ethyl ester 
• 62-53-3 aniline 
• 5292-53-5 diethyl benzalmalonate 
• 100-52-7 benzaldehyde 
• 70-11-1 α-bromoacetophenone 
• 70916-14-2 triethyl-(2-oxo-2-phenylethyl)ammonium bromide 
• 97301-06-9 1-Phenacyl-4-aza-1-azonia-bicyclo<2.2.2>octan-bromid 
• 24472-77-3 trimethyl-(2-oxo-2-phenylethyl)-ammonium bromide 
• 124-38-9 carbon dioxide 
• 27973-23-5 3-methoxy-1H-indene 

Downstream Products

• 14381-42-1 Indan-1-carboxylic acid 
• 88-99-3 benzene-1,2-dicarboxylic acid 
• 185122-64-9 Methyl 3-hydroxyimino-1-indanecarboxylate 
• 111634-91-4 Methyl (+/-)-cis-3-amino-1-indanecarboxylate 
• 185122-65-0 Methyl (+/-)-trans-3-amino-1-indanecarboxylate 
• 29427-70-1 methyl 3-oxo-2,3-dihydro-1H-indene-1-carboxylate 
• 1444393-70-7 C₂₇H₂₈N₆O₃ 
• 921213-08-3 1-(tetrahydropyrrole-1-methyl)-2-(2,3-dihydroinden-3-one-1-carbonyl)-1,2,3,4-tetrahydroisoquinoline 
• 2387-23-7 1,3-Dicyclohexylurea 
• 93321-72-3 2-benzyl-3-oxo-1-indancarboxylic acid 
• 29427-71-2 3-Carboxamido-1-indanon 
• 132205-76-6 1-cyano-5-chloro-2,3-dihydro-1H-indene 
• 91948-71-9 C₂₁H₂₁NO₄S 
• 240403-56-9 N-<(1-oxoindan-3-yl)carbonyl>-4-(p-fluorobenzoyl)piperidine bis(ethylene ketal) 

Relevant articles and documents

Synthesis of new 6-substituted purinyl-5′-nor-1′- homocarbanucleosides based on indanol

A series of new 6-substituted purinyl-5′-nor-1′- homocarbanucleosides based on indanol were synthesized from (±)-cis-3- hydroxymethyl-1-indanol, an appropriately functionalized derivative of which was reacted with 6-chloropurine in the presence of NaH and

Preparation method and application of tetrahydroisoquinoline derivative

The invention discloses a preparation method of a tetrahydroisoquinoline derivative. The tetrahydroisoquinoline derivative is prepared by subjecting 1-(tetrapyrrolidin-1-yl)-1,2,3,4-tetrahydroisoquinoline and 2,3-dihydro-indene-3-one-1-carboxylic acid to condensation. Process conditions are optimized so that preparation steps are simplified. Agents used in the preparation are pollution free. The prepared tetrahydroisoquinoline derivative 1-(tetrapyrrolidin-1-methyl)-2-(2,3-dihydro-indene-3-one-1-carbonyl)-1,2,3,4-tetrahydroisoquinoline can provide good calming effect against neuropathic pain.The tetrahydroisoquinoline derivative has high medical value in drug compositions for pain treatment and in replacing dependent analgesics, such as morphine.

Compound as potassium channel modulator

The invention relates to a compound as a potassium channel modulator, which is a compound of a formula (I) or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof is effective for curing and preventing diseases and symptoms influenced by the activity of potassium ion channels.

SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE

Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

Discovery, stereospecific characterization and peripheral modification of 1-(pyrrolidin-1-ylmethyl)-2-[(6-chloro-3-oxo-indan)-formyl]-1,2,3,4-tetrahydroisoquinolines as novel selective κ opioid receptor agonists

A novel series of 1-(pyrrolidin-1-ylmethyl)-2-[(3-oxo-indan)-formyl]-1,2,3,4-tetrahydroisoquinoline derivatives maj-3a-maj-3u were synthesized and evaluated in vitro for their binding affinity at κ-opioid receptors. Maj-3c displayed the highest affinity for κ-opioid receptors (Ki = 0.033 nM) among all the compounds evaluated. Furthermore, all four stereoisomers of compound 3c were prepared, and (1S,18S)-3c was identified as the most potent (Ki = 0.0059 nM) κ-opioid receptor agonist among the four stereoisomers. Maj-3c produced significant antinociception (ED50 = 0.000406 mg kg-1) compared to U-50,488H and original BRL 52580 in the acetic acid writhing assay, but its strong sedative effect (ED50 = 0.000568 mg kg-1) observed in the mouse rotation test reduced its druggability. To minimize the central nervous system side effects, a series of hydroxyl-containing analogs of maj-3c were synthesized, and maj-11a was found to be a potent κ-opioid receptor agonist (Ki = 35.13 nM). More importantly, the dose for the sedative effect (ED50 = 9.29 mg kg-1) of maj-11a was significantly higher than its analgesic dose (ED50 = 0.392 mg kg-1), which made it a promising peripheral analgesic candidate compound with weak sedative side effects.

Rhodium-catalyzed C-H activation of phenacyl ammonium salts assisted by an oxidizing C-N bond: A combination of experimental and theoretical studies

Rh(III)-catalyzed C-H activation assisted by an oxidizing directing group has evolved to a mild and redox-economic strategy for the construction of heterocycles. Despite the success, these coupling systems are currently limited to cleavage of an oxidizing

TETRAHYDRO ISOQUINOLINE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF

A kind of tetrahydro isoquinoline derivatives (I), their preparation methods, medicine compositions and medicinal uses thereof, especially their uses as κ-opioid receptor excitant in pain relieving, which belongs to the medicine chemistry. The substituents R1, R2, R3, R4 of general formula (I) are defined as the description.

Tetrahydro isoquinoline derivatives, preparation methods and medicinal uses thereof

A kind of tetrahydro isoquinoline derivatives (I), their preparation methods, medicine compositions and medicinal uses thereof, especially their uses as kappa-opioid receptor excitant in pain relieving, which belongs to the medicine chemistry. The substituents R1, R2, R3, R4 of general formula (I) are defined as the description.

Aminoindanes

The present invention relates to therapeutically active novel aminoindanes of formula (I). Also provided is a method of preparing compounds of formula (I), and pharmaceutical compositions comprising the compounds. The novel compounds act as modulators of

Structure-based design of peptidomimetic antagonists of p56lck SH2 domain

Starting from the tetrapeptide Ac-pYEEI-NHMe and using a structure-based approach, we have designed and synthesised a peptidomimetic ligand for p56lck SH2 domain containing a conformationally restricted replacement for the two glutamate residue